Apeloa Pharmaceuticals marked an outstanding turnout at pharmaceutical conference CPHI China this year, receiving throngs of visitors at its booth and engaging in fruitful discussions with guests.

This year, Apeloa’s team met and spoke with new and existing customers about strategic partnerships, globalization, R&D investments, platform building, technical capacity enhancement and high-end capacity development.

The company also reflected on its latest triumphs. Apeloa’s business revenue has grown at a steady clip in recent years, reaching a historic milestone of 10 billion RMB in 2022 for the first time. The company has also invested $1 billion towards enhancing its manufacturing and R&D capabilities.

As a major drug manufacturer and prominent partner of other companies worldwide, Apeloa is an annual presence at CPHI China since the exhibition first entered China in 2001. The conference is a prominent platform industrywide, drawing pharmaceutical companies and distributors from across the world.

Apeloa’s high-quality growth was received well by its partners and clients, reinforcing their resolve for increased collaboration and expansion of business.

Yuchuan Gong, Vice President and Head of Small Molecule CMC at BeiGene, remarked that “what touches me deeply about our collaboration is Apeloa’s sense of service,” he said. “Apeloa has consistently gone above and beyond with the most enthusiastic and meticulous service for our projects, and we both are committed to fostering cooperation with the utmost sincerity, promoting our partnership towards a broader future.”

More about Apeloa Pharmaceuticals

Apeloa Pharmaceuticals, founded in 1989, is a healthcare company that manufactures and markets raw material medicines and preparations, including antitumour, antivirus, anti-infectious, cardiovascular and other medicines. It specialises in API, CDMO and Finished Dosage Form (FDF). The company is a subsidiary of Hengdian Group, and is listed on the main board of the Shenzhen Stock Exchange (SZSE: 000739).

Currently, Apeloa has eight manufacturing bases with a chemical synthesis capacity exceeding 11,000m³ and fermentation capacity exceeding 6,000m³. It has established and operates its own analytical testing center and safety laboratory, which have received the CNAS (China National Accreditation Service) Certificate of Accreditation, which certifies operations for laboratories in China.

Apeloa has already established three major technical platforms: Fluid Chemistry, Crystals and Powders, and Synthetic Biology and Enzymatic Catalysis. It is currently in the process of developing three additional technology platforms: Protac, ADC and Peptides. In the next two years, Apeloa aims to increase its R&D staff to more than 2000 people.

Press Inquiries 

E-mail: press@hengdian.com